Journey for Control of Diabetes Study (0431-111)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Behavior change and self-efficacy are key for patients with diabetes to sustain blood sugar goals, but most care systems do not provide effective support to assist patients in successful ongoing self-management. After initial education, many programs are limited by allowable Medicare reimbursement for diabetes education which currently requires physician referral and cannot exceed two hours of training per year for a beneficiary, plus one hour of nutritional services. These services are usually provided either on an individual basis or occasionally through a traditional group class approach. For patients with established type 2 diabetes who are not achieving optimal glycemic control, we propose to develop and formally evaluate in a randomized trial a novel group experience to educate and motivate patients with established type 2 called IDEA, (Interactive Dialogue to Educate and Activate). This multi-site, randomized, prospective trial will randomize 621 patients with inadequately blood sugar control levels to one of 3 study groups: (1) IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients (2) Individual Education (IE) - patients receive 2 hours with a nurse educator and 1 hour with a dietitian, and (3) Usual care (UC)- patients receive no research intervention. The primary analyses will involve mixed model regression to assess whether IDEA improves outcomes compared to IE and UC. Blood sugar level, blood pressure, and lipids will be evaluated 6 and12 months post-randomization and behavioral, emotional, and satisfaction outcomes through survey at baseline, 3, 6, 9 and 12 months. Depending on 12 month results, a longitudinal four year post intervention analysis is planned to assess sustainability of treatment effects and cost-effectiveness.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes Mellitus |
Behavioral: Interactive Dialogue to Educate and Activate (IDEA) Behavioral: Individual Education (IE) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Journey for Control of Diabetes Study |
- Program satisfaction, behavioral and emotional outcomes. [ Time Frame: 3, 6, 9, 12 months after implementation of intervention ] [ Designated as safety issue: No ]
- Blood sugar level, blood pressure, lipids, cost, comorbidities. [ Time Frame: 6, 12, 18, 24, 36, and 48 months after intervention ] [ Designated as safety issue: No ]
| Enrollment: | 621 |
| Study Start Date: | May 2008 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
IDEA
|
Behavioral: Interactive Dialogue to Educate and Activate (IDEA)
IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
|
|
Active Comparator: 2
IE
|
Behavioral: Individual Education (IE)
IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
|
|
No Intervention: 3
UC: Patients receive no research intervention.
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 Diabetes Mellitus
Exclusion Criteria:
- Gestational diabetes
- Type 1 Diabetes Mellitus
Contacts and Locations| Principal Investigator: | HealthPartners | Investigators/Collaborators |
| Principal Investigator: | Lovelace Clinic Foundation | Investigators/Collaborators |
| Study Director: | Medical Monitor | Merck |
More Information
No publications provided by Merck
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Merck |
| ClinicalTrials.gov Identifier: | NCT00652509 History of Changes |
| Other Study ID Numbers: | 2008_510, MK-0431-111 |
| Study First Received: | March 31, 2008 |
| Last Updated: | August 29, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013